Anzutresgene Autoleucel

安组基奥仑赛

Report date: 2026/04/22 20:01:10

Base Information

Drug NameAnzutresgene Autoleucel

Drug Alias NameIMA-203

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityMelanoma antigen preferentially expressed in tumors modulators

TargetsMelanoma antigen preferentially expressed in tumors

Therapy Area/IndicationsSkin MelanomaSolid tumoursSarcoma, Synovial

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesGermany +[4]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesImmatics Us Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmatics Us Inc

Inactive CompaniesN/A

Active IndicationsSkin MelanomaSolid tumoursSarcoma, Synovial

Inactive IndicationsN/A

Other Information

ATC CodeN/A